Pds biotechnology reports inducement grant under nasdaq listing rule 5635(c)(4)

Princeton, n.j., may 09, 2025 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (“pds biotech” or the “company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that on may 5, 2025, pds biotech granted a nonstatutory stock option to purchase 5,000 shares of common stock to an employee in its clinical department as a material inducement to such employee's employment and in accordance with nasdaq listing rule 5635(c)(4) and pds biotech's 2019 inducement plan, as amended, which was adopted on june 17, 2019, and provides for the granting of equity awards to new employees of pds biotech.
PDS Ratings Summary
PDS Quant Ranking